लेडिपासविर और सोफोसबुविर और लोरलाटिनिब का इंटरैक्शन

Use of ledipasvir and sofosbuvir with P-gp inducers is not recommended.

John's wort) may decrease ledipasvir and sofosbuvir plasma concentrations, leading to reduced therapeutic effect of ledipasvir and sofosbuvir, and the use with P-gp inducers is not recommended with ledipasvir and sofosbuvir [see Warnings and Precautions (5.3) ] .

John's wort, a P-gp inducer, is not recommended [see Warnings and Precautions (5.3) ].

Risk of Reduced Therapeutic Effect Due to Use with P-gp Inducers The concomitant use of ledipasvir and sofosbuvir and P-gp inducers may significantly decrease ledipasvir and sofosbuvir plasma concentrations and may lead to a reduced therapeutic effect of ledipasvir and sofosbuvir.

Therefore, the use of ledipasvir and sofosbuvir with P-gp inducers (e.g., rifampin, St.